{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:45Z","timestamp":1793383185015,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, largely due to its profoundly immunosuppressive tumor microenvironment (TME) and intrinsic resistance to conventional therapies. Radiotherapy (RT), traditionally valued for its cytotoxic effects, has recently been recognized for its immunomodulatory potential. This mini-review explores the multifaceted interactions between RT and the PDAC immune microenvironment, highlighting mechanisms such as induction of immunogenic cell death, enhancement of antigen presentation, modulation of cytokine and chemokine profiles, and upregulation of immune checkpoint molecules. These effects may transform immunologically \u201ccold\u201d tumors into \u201chot\u201d ones, providing a rationale for combination strategies with immunotherapy. However, the dense desmoplastic stroma, abundance of regulatory T cells, and myeloid-derived suppressor cells within PDAC present substantial challenges that hinder effective immune activation. Advances in single-cell and spatial transcriptomic technologies offer new opportunities to better characterize the TME and guide personalized treatment strategies. By synthesizing mechanistic insights and clinical evidence, this review underscores the potential of integrating RT with immunotherapy to overcome resistance mechanisms and improve therapeutic outcomes in PDAC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1619946","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:27:23Z","timestamp":1751520443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Radiotherapy and immune microenvironment crosstalk in pancreatic cancer: a comprehensive review of current insights and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Yucheng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2023.05.03","article-title":"Epidemiology of pancreatic cancer: New version, new vision","volume":"35","author":"Luo","year":"2023","journal-title":"Chin J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100972","article-title":"PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC\/LAPC: A biomolecular exploratory, phase II trial","volume":"4","author":"Du","year":"2023","journal-title":"Cell Rep Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6322-4","article-title":"Chemotherapy with or without definitive radiation therapy in inoperable pancreatic cancer","volume":"25","author":"Zhong","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"Jama"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12876-023-02739-x","article-title":"Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","article-title":"Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial","volume":"21","author":"Janssen","year":"2021","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/jca.92502","article-title":"Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2024.029","article-title":"Tumor stroma as a therapeutic target for pancreatic ductal adenocarcinoma","volume":"32","author":"Lee","year":"2024","journal-title":"Biomol Ther (Seoul)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9555","DOI":"10.3390\/ijms25179555","article-title":"The role of tumor microenvironment in pancreatic cancer immunotherapy: current status and future perspectives","volume":"25","author":"Poyia","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma","volume":"145","author":"Ene-Obong","year":"2013","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1038\/s41598-020-64408-3","article-title":"Transcriptional upregulation of NLRC5 by radiation drives STING- and interferon-independent MHC-I expression on cancer cells and T cell cytotoxicity","volume":"10","author":"Zebertavage","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15010927","article-title":"The effect of radiation on the immune response to cancers","volume":"15","author":"Park","year":"2014","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519855595","article-title":"Radiotherapy activates autophagy to increase CD8(+) T cell infiltration by modulating major histocompatibility complex class-I expression in non-small cell lung cancer","volume":"47","author":"Zeng","year":"2019","journal-title":"J Int Med Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-023-01139-8","article-title":"Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations","volume":"21","author":"Wu","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.21037\/atm-22-6049","article-title":"Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review","volume":"10","author":"Wang","year":"2022","journal-title":"Ann Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2102611118","DOI":"10.1073\/pnas.2102611118","article-title":"Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads","volume":"118","author":"Lussier","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e138740","DOI":"10.1172\/JCI138740","article-title":"Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control","volume":"131","author":"Lhuillier","year":"2021","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/cancers15030768","article-title":"Combination, modulation and interplay of modern radiotherapy with the tumor microenvironment and targeted therapies in pancreatic cancer: which candidates to boost radiotherapy","volume":"15","author":"Benkhaled","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-1190","article-title":"Quantitative spatial profiling of immune populations in pancreatic ductal adenocarcinoma reveals tumor microenvironment heterogeneity and prognostic biomarkers","volume":"82","author":"Mi","year":"2022","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1038\/s41598-025-86950-8","article-title":"Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e151797","DOI":"10.1172\/jci.insight.151797","article-title":"Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells","volume":"6","author":"Hinterbrandner","year":"2021","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12967-024-05307-3","article-title":"Progress of single-cell RNA sequencing combined with spatial transcriptomics in tumour microenvironment and treatment of pancreatic cancer","volume":"22","author":"Zhu","year":"2024","journal-title":"J Transl Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC).","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol."},{"key":"B38","unstructured":"Amsterdam U Data from: PANFIRE-III: Irreversible Electroporation Combined With Nivolumab and CpG in Metastatic Pancreatic Cancer (NCT04612530)\n          \n          \n          2020"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e000351","DOI":"10.1136\/jitc-2019-000351","article-title":"Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer","volume":"8","author":"Fujiwara","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02935-3","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1619946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:27:27Z","timestamp":1751520447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1619946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1619946"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1619946","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"article-number":"1619946"}}